Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis

BMJ Case Rep. 2021 Feb 22;14(2):e240615. doi: 10.1136/bcr-2020-240615.

Abstract

Sarcoidosis is a multisystem inflammatory disorder of uncertain aetiology. There are numerous case reports of sarcoidosis occurring during treatment with biological immunotherapies. Here, we describe the case of a 52-year-old woman with psoriatic arthritis who developed multisystem sarcoidosis while being treated with secukinumab (anti-interleukin-17A) therapy which, to our knowledge, is the first such case. We discuss existing literature and hypothesise that IL-17 blockade may precipitate the development of granulomatous disease.

Keywords: biological agents; drugs: musculoskeletal and joint diseases.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Arthritis, Psoriatic* / drug therapy
  • Female
  • Humans
  • Middle Aged
  • Sarcoidosis* / chemically induced
  • Sarcoidosis* / diagnosis
  • Sarcoidosis* / drug therapy

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • secukinumab